Search | Clinical Trials Finder

Conditions: Primary or Secondary Hypogonadism, Constitutional Delay in Growth and Puberty (CDGP)
Interventions: Testosterone Gel (1%); Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 13 Years to 17 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 14 more

Conditions: Hypothalamic Amenorrhea, Functional, Hypothalamic Amenorrhea, Functional Hypogonadotropic Hypogonadism
Interventions: Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24), REVEAL Questionnaire; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Secondary Hypogonadism
Interventions: Androxal; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 31
States / cities: Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more

Conditions: Amenorrhea, Hypogonadotropic Hypogonadism, Kallmann's Syndrome
Interventions: Frequent baseline blood sampling; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadism, Kallmann Syndrome
Interventions: Testicular biopsy, gonadotropin releasing hormone (GnRH), follicle stimulating hormone (FSH); Procedure · Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadism
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1993 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypogonadotropic Hypogonadism, Amenorrhea, Kallmann's Syndrome
Interventions: GnRH, Pump; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Secondary Hypogonadism
Interventions: Androxal, AndroGel, Placebo; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 68 Years · Male only
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 18
States / cities: Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more

Conditions: Primary Amenorrhea With Hypogonadotropic Hypogonadism
Interventions: Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 33
States / cities: Tempe, Arizona • San Francisco, California • Aurora, Colorado + 28 more

Conditions: Male Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
Interventions: Testosterone undecanoate; Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Male Hypogonadism
Interventions: Oral testosterone undecanoate (containing 300 mg T); Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Torrance, California

Conditions: Hypogonadism, Hypogonadotropic, Obesity
Interventions: anastrozole (1 mg/day), Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Secondary Hypogonadism
Interventions: Androxal; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 19 Years to 60 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Hypogonadism, Male
Interventions: Testosterone enanthate; Combination Product
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 12 Years to 17 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 20
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 17 more

Conditions: Hypogonadism, Hypogonadotropic
Interventions: Clomiphene, Placebo; Drug
Lead sponsor: Sandeep Singh Dhindsa, M.D., F.A.C.E; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Secondary Hypogonadism
Interventions: Androxal (enclomiphene citrate), Testosterone; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Hypogonadotropic Hypogonadism, Kallmann Syndrome, GnRH Deficiency, PCOS, Polycystic Ovarian Syndrome, Hyperprolactinemia
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadotropic Hypogonadism, Type 2 Diabetes
Interventions: testosterone, clomiphene, placebo; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypogonadotropic Hypogonadism
Interventions: Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG); Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Genetic Disorder, Infertility, Hypogonadism, Amenorrhea
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 6 Weeks to 120 Years
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 2
States / cities: Bethesda, Maryland • Research Triangle Park, North Carolina

Conditions: Hypogonadotropic Hypogonadism
Interventions: kisspeptin 112-121, leuprolide acetate; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism
Interventions: kisspeptin 112-121; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Secondary Hypogonadism
Interventions: Placebo, topical testosterone, Androxal; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 21 Years to 65 Years · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 18
States / cities: Garden Grove, California • Sacramento, California • San Diego, California + 11 more

Conditions: Hypogonadism
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 200 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism

The REgistry of Very Early Estrogen and AnovuLation

Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

Baselines in Reproductive Disorders

Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism

Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement

Pulsatile GnRH in Anovulatory Infertility

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

LutrePulse Hypogonadotropic Hypogonadism

Pharmacokinetic Study to Determine Time to Steady-state

Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation

Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Hypogonadotropic Hypogonadism in Obese Young Males

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

Kisspeptin Administration in the Adult

Hypogonadism in Young Men With Type 2 Diabetes

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

Inherited Reproductive Disorders

Kisspeptin Administration Subcutaneously to Patients With IHH

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

Psychological Outcomes in Isolated GnRH Deficiency